

Preseptal and Orbital Cellulitis

Majida Gaffar, MD Eric Hoppa, MD Scott Schoem, MD Julie Quistorff, APRN







What is a Clinical Pathway?



An evidence-based guideline that decreases unnecessary variation and helps promote safe, effective, and consistent patient care.

Pathway Objectives



- To quickly identify patients with orbital cellulitis who may require surgery
- To identify those patients who require a CT scan
- To improve coordination of the multiple subspecialists often involved in care of this group of patients
- To standardize antibiotics for these infections

Why is the Pathway Necessary?



- Orbital cellulitis is a fairly rare condition but has significant complications
- Requires the coordinated efforts of multiple services
- Important to define the responsibilities of each service
- CT imaging of the orbit is needed to determine the need for surgery, but currently there
 is no standard for when to get imaging
- Need to standardize recommended antibiotics

- This is the Pre-septal and Orbital Cellulitis Clinical Pathway.
- We will be reviewing each component in the following slides.

CLINICAL PATHWAY:

Preseptal & Orbital Cellulitis

Inclusion Criteria: eye swelling concerning for preseptal or orbital cellulitis


Exclusion Criteria: evidence of non-cellulitic cause of eye swelling (e.g., allergy, chalazion, conjunctivitis, dacryocele), supero-lateral abscess on CT (will need orbital surgeon), posterior table erosion of the frontal sinus bone with brain abscess, any patient requiring neurosurgical involvement

Initial Evaluation

- History including diplopia, systemic symptoms Physical exam findings, including extent of eyelid edema/erythema; presence of proptosis; ocular motility/pain with eye
- movement; pupillary reaction/afferent pupillary defect; vision with Snellen chart, if possible Labs: CBC with differential, CRP (unless mild preseptal cellulitis signs and/or attending discretion)
- If ocular discharge: obtain bacterial culture and wound MSSA/MRSA PCR on ocular discharge; if unable to obtain, consider MSSA/MRSA PCR from nares to determine if MRSA coverage is needed

If ill-appearing or high suspicion of orbital cellulitis: obtain blood culture

Place Ophthalmology consult for: - Urgent calls for any orbital involvement (clinically or on CT) or - If ENT taking to OR



Consider CT or MRI If rapidly progressing, obtain Cl Discuss with consulting services

DISCHARGE CRITERIA: Vision back to baseline, clinical improvement, afebrile, follow up plan in place DISCHARGE INSTRUCTIONS: Follow up with PCP; Complete course of antibiotics, Ophthalmology f/u in 1-2 weeks if involved during admission

If Orbital Cellulitis with concern for CNS involvement on imaging: Treat off pathway and consult Neurosurgery and Infectious Diseases (see Appendix A for work up and antibiotic considerations)

- DISCHARGE ANTIBIOTICS (not to be used if there is CNS involvement) Duration: 5-7 days for preseptal cellulitis (if sinusitis, longer therapy may be needed per ENT/ID); ≥2 weeks for orbital cellulitis as determined by ENT/ID
- If sensitivities are available, discuss appropriate antibiotic choice with Infectious Diseases/ASP.
- Preferred PO antibiotic if no PCN allergy or if on Ampicillin/Sulbactam (Unasyn): Amoxicillin/Clavulanate PO: <40 kg or unable to take tablets: 600 mg/5 mL (ES) suspension: 90 mg/kg/day div BID (max 1000 mg/dose); >40 kg and can take tablets: 875 mg BID tablets
- If PCN allergy and IV vancomycin or clindamycin not used: Consider Penicillin Allergy Delabeling Pathway to assess if patient can utilize amox/clav. If PCN allergy confirmed: start cefuroxime PO 30 mg/kg/day div 2 doses (max 500 mg/dose) [Note: only 250 and 500 mg tablets are commercially available; ensure availability for home prior to discharge]. If cefuroxime not available, consult ID

If patient was on IV Vancomycin/IV Clindamycin or MRSA nasal PCR/culture positive: discuss with ID to add anti-MRSA antibiotic to antibiotic regimen.

CONTACTS: MAJIDA GAFFAR, MD | ERIC HOPPA, MD | HAREEM PARK, MD | SCOTT SCHOEM, MD | IAN MICHELOW, MD JULIE QUISTORFF, APRN



@2019 Connecticut Children's Medical Center. All rights reserved

Inclusion Criteria: eye swelling concerning for preseptal or orbital cellulitis


Exclusion Ofterla: evidence of non-cellulitic cause of eye swelling (e.g., allergy, chalazion, conjunctivitis, dacryocele), supero-lateral ab scess on CT (will

Inclusion Criteria: eye swelling concerning for preseptal or orbital cellulitis

Exclusion Criteria: evidence of non-cellulitic cause of eye swelling (e.g., allergy, chalazion, conjunctivitis, dacryocele), supero-lateral abscess on CT (will need orbital surgeon), posterior table erosion of the frontal sinus bone with brain abscess, any patient requiring neurosurgical involvement

Inclusion Criteria: eye swelling and concern for cellulitis

*NOTE: If cellulitis is clearly the result of a break in the skin (i.e., infected insect bite), consider using the Skin and Soft Tissue Infection (SSTI) pathway.



CONTACTS: MAJIDA GAFFAR, MD | ERIC HOPPA, MD | EBLA ABD ALRAHMAN, MD | SCOTT SCHOEM, MD

LAST UPDATED: 09.27.21

Connecticu Children

Initial evaluation:

The initial evaluation helps determine if orbital cellulitis is present.

Symptoms and signs that indicate a concern for orbital cellulitis and subsequent need for a CT include:

- Pain with eye movement
- EOM's restricted or diplopia
- Proptosis
- ANC >10,000 (ANC = WBC x [%neutrophils + %bands])
- Cannot assess above due to extensive eyelid edema


The provider may always order a CT if there is clinical suspicion.

There is now a new suggestion to obtain bacterial culture and wound MSSA/MRSA PCR of ocular discharge or obtain MSSA/MRSA PCR from nares to determine if MRSA coverage is needed

If ill-appearing or high suspicion of orbital cellulitis: obtain blood culture

CLINICAL PATHWAY: Preseptal & Orbital Cellulitis

THIS PATHWAY SERVES AS A GUIDE AND DOES NOT REPLACE CLINICAL JUDGMENT.



CONTACTS: MAJIDA GAFFAR, MD | ERIC HOPPA, MD | EBLA ABD ALRAHMAN, MD | SCOTT SCHOEM, MD

LAST UPDATED: 09.27.2






Timely communication is essential if there is a high clinical suspicion for orbital cellulitis based on the initial examination alone.

- If high clinical suspicion, formally consult ophthalmology right away, and then consult ID and ENT if CT is positive for orbital cellulitis.
- If positive CT, administer steroids.

CLINICAL PATHWAY: Preseptal & Orbital Cellulitis

THIS PATHWAY SERVES AS A GUIDE AND DOES NOT REPLACE CLINICAL



CONTACTS: MAJIDA GAFFAR, MD | ERIC HOPPA, MD | EBLA ABD ALRAHMAN, MD | SCOTT SCHOEM, MD


AST UPDATED: 09.27.21



- If there is low suspicion for orbital cellulitis and/or the CT is negative, the diagnosis is likely preseptal cellulitis due to a dental or sinus source.
- If the source of infection is from the skin, we recommend following the Skin and Soft Tissue Infection Pathway – which outlines more appropriate antibiotics based on likely pathogens.
- Those with preseptal cellulitis may either be discharged or admitted based on specific criteria.

CLINICAL PATHWAY: Preseptal & Orbital Cellulitis

THIS PATHWAY
SERVES AS A GUIDE
AND DOES NOT
REPLACE CLINICAL
HUDGMENT



CONTACTS: MAJIDA GAFFAR, MD | ERIC HOPPA, MD | EBLA ABD ALRAHMAN, MD | SCOTT SCHOEM, MD

LAST UPDATED: 09.27.2






Determining Admitting Service

- Orbital cellulitis with surgical intervention: admit to ENT with Pediatric Hospital Medicine (PHM) co-management
 Ophthalmology will follow
- Orbital cellulitis but surgery not indicated: admit to PHM
 - ENT and Ophthalmology will follow
- Preseptal Cellulitis: admit to PHM

CLINICAL PATHWAY:

Preseptal & Orbital Cellulitis

THIS PATHWAY
SERVES AS A GUID
AND DOES NOT
REPLACE CLINICA
JUDGMENT.



CONTACTS: MAJIDA GAFFAR, MD | ERIC HOPPA, MD | EBLA ABD ALRAHMAN, MD | SCOTT SCHOEM, MD



Inpatient assessments

- Pediatric provider (resident, APP) to do vision checks with Snellen chart upon admission, then twice daily.
 - MUST document results in the chart (particularly if not able to be done)
- Contact ENT and Ophthalmology <u>IMMEDIATELY</u> if there is a change!
- Snellen charts will be available in pod B of med/surg units.

CLINICAL PATHWAY: Preseptal & Orbital Cellulitis

THIS PATHWAY SERVES AS A GUIDE AND DOES NOT REPLACE CLINICAL JUDGMENT.

Exclusion Orteria: evidence of non-cellulitic cause of eye swelling (e.g., allergy, chalazion, conjunctivitis, dacryocele), supero-lateral abscess on CT (will need orbital surgeon), posterior table erosion of the frontal sinus bone with brain abscess, any patient requiring neurosurgical involvement Onht halm older consult for History including diplopia, systemic symptoms Physical exam findings, including: for any Extent of evelid edema/erythem orbital Presence of proptosis involvemen Ocular motility/pain with eye movement (clinically or on CT) OR Pupillary reaction/afferent pupillary defect If ENT taking to OR labs: CBC w/differential, CRP (unless mild pre septal cellulitis signs and/or attending discretion); If ocular discharge, obtain bacterial cultur

Inpatient Management:

- Patients >5 years old: General pediatric provider (resident, APP) to complete vision checks with Snellen chart on admission and BID (If unable to complete, must document in chart.)
- Continue to monitor for development of orbital cellulitis
- NPO after midnight if strong possibility of surgery
- If orbital cellulitis confirmed on CT:
 - Dexa methasone IV 0.5 mg/kg x1 (max 10 mg/dose) if not already given
 - Consult Infectious Diseases (ID)
 - If signs of systemic illness or intracranial infection, obtain blood culture before antibiotics given, if possible.
- If recent history of trauma or surgery: consult ID as antibiotic recommendations would be different than those listed below
 Preseptal or Orbital Cellulitis without CNS involvement on imaging:
- Ampicillin/Sulbactam IV based on ampicillin component: 200 mg/kg/day div q6hr (max 2,000 mg ampicillin/dose)
 - If preseptal cellulitis and stable: can choose Amoxicillin/Clavulanate PO: <40 kg or unable to take tablets: 600 mg/5 mL (ES) suspension: 90 mg/kg/day div BID (max 1000 mg/dose); >40 kg and can take tablets: 875 mg BID tablets
 - If PCN allergy: Clindamycin PO/IV 30-40 mg/kg/day div q8hr (max 600 mg/dose) AND Ceftriaxone IV 75 mg/kg/day div q12hr (max 2 g/DAY)
- If concern for MRSA, obtain MRSA nasal PCR. If PCR positive, obtain MRSA nasal culture and <u>add</u> the below:
 - If preseptal and stable: add Clindamycin PO/IV 30 mg/kg/day div q8hr (max 600 mg/dose) until susceptibilities finalize (unless already on Clindamycin for PCN allergy)
 - If ill-appearing or orbital: add Vancomycin IV: <52 weeks PMA[†]/about <3 mo old: 15 mg/kg q8hr or as determined by pharmacy based on estimated AUC; ≥52 weeks PMA[†]/about ≥3 months old − 11 years old: 70 mg/kg/day div q6hr (max 3 g/day); ≥12 yrs old: 60 mg/kg/day div q8hr (max 3 g/day) [†PMA (Post-Menstrual Age) = gestational age + postnatal age]
 - If renal function present, substitute Vancomycin with Linezolid IV: <12 yrs old: 30 mg/kg/day div q8hr (max 600 mg/dose); ≥12 yrs old: 600 mg q12hr (if ≥12 yrs old and <45 kg: 20 mg/kg/day div q12hr, max 600 mg/dose)

If Orbital Cellulitis with concern for CNS involvement on imaging:

Treat off pathway and consult Neurosurgery and Infectious Diseases (see Appendix A for work up and antibiotic considerations)

If PCN altergy, or if on Clindamycin IV with Certrioxone:
 Clindamycin PO 30-40 mg/kg/day div q6-8hr (max 600 mg/dose) AND

Celdinir PO 14 mg/kg/day dw BID (max 300 mg/dose) or Levofl oxadn PO 6 mo-4 yrs: 20 mg/kg/day div q12hr; 5-9 yrs: 14 mg/kg/day div q12hr; 10 yrs: 10 mg/kg once daily (max 750 mg/day)

10 yrs: 10 mg/kg once daily (max 750 mg/day)
If on Vancomycin:

ADD Clindamycin PO 30-40 mg/kg/day div q6-8hr (max 600 mg/dose) (continue Amoxicillin/Clavulanate or Cefdinir/Levoflaxacin as appropriate)

Discharge Instructions:

omplete course of antibiotics, Ophthalmology f/u in 1-2 weeks if involved during admiss

Connecticut Children's

Antibiotics:

- Typical organisms for orbital cellulitis are Staph aureus, Strep pneumo, other streptococci, anaerobes
- Consider Haemophilus influenza B in the unimmunized patient
- Likely pathogens depend on site of origin of the infection → thus, follow SSTI pathway for skin sources, and this pathway for sinus or dental sources of infection
- If orbital cellulitis confirmed, consult
 ID and administer steroids if not already completed
- Note that antibiotics differ based on suspicion of CNS involvement. In this case, consult Neurosurgery and ID for further care recommendations

CLINICAL PATHWAY:

SERVES AS A GUID AND DOES NOT REPLACE CLINICA JUDGMENT

Preseptal & Orbital Cellulitis

Exclusion Ofteria: evidence of non-cellulitic sues of eve swelling concerning for preseptal or orbital cellulities

Exclusion Ofteria: evidence of non-cellulitic sues of eve swelling (e.g., allergy, chalazion, conjunctivitis, darcyocele), supero-lateral abscess on CT [will need or bital surgeon), posterior table er osion of the frontal sinus bone with brain abscess, any patient requiring neurosurgical involvement

- History including diplopia, systemic symptoms

- Physical axam findings, including:
- Extent of eyelid edem aleynthema
- Presence of propto sis
- Ocular motifity/pain with eye movement
- Pupillary reaction/afferent pupillary defect
- Wision with Snellen chart, if possible
- Labs: CRC widifferential, CRP jurless smill pre septal cellulitis signs and/or attending discretion); If ocular discharge, obtain bacterial culture
- Text of the control of the cont

Inpatient Management:

- Patients >5 years old: General pediatric provider (resident, APP) to complete vision checks with Snellen chart on admission and BID (If unable to complete, must document in chart.)
- Continue to monitor for development of orbital cellulitis
- NPO after midnight if strong possibility of surgery
- If orbital cellulitis confirmed on CT:
 - Dexa methasone IV 0.5 mg/kg x1 (max 10 mg/dose) if not already given
 - Consult Infectious Diseases (ID)
 - If signs of systemic illness or intracranial infection, obtain blood culture before antibiotics given, if possible.
- If recent history of trauma or surgery: consult ID as antibiotic recommendations would be different than those listed below
 Preseptal or Orbital Cellulitis without CNS involvement on imaging:
- Ampicillin/Sulbactam № based on ampicillin component: 200 mg/kg/day div q6hr (max 2,000 mg ampicillin/dose)
 - If preseptal cellulitis and stable: can choose Amoxicillin/Clavulanate PO: <40 kg or unable to take tablets: 600 mg/5 mL (ES) suspension: 90 mg/kg/day div BID (max 1000 mg/dose); >40 kg and can take tablets: 875 mg BID tablets
 - If PCN allergy: Clinda mycin PO/IV 30-40 mg/kg/day div q8hr (max 600 mg/dose) AND Ceftriaxone IV 75 mg/kg/day div q12hr (max 2 g/DAY)
- If concern for MRSA, obtain MRSA nasal PCR. If PCR positive, obtain MRSA nasal culture and <u>add</u> the below:
 - If preseptal and stable: add Clindamycin PO/IV 30 mg/kg/day div q8hr (max 600 mg/dose) until susceptibilities finalize (unless already on Clindamycin for PCN allergy)
 - If ill-appearing or orbital: add Vancomycin IV: <52 weeks PMA[†]/about <3 mo old: 15 mg/kg q8hr or as determined by pharmacy based on estimated AUC; ≥52 weeks PMA[‡]/about ≥3 months old − 11 years old: 70 mg/kg/day div q6hr (max 3 g/day); ≥12 yrs old: 60 mg/kg/day div q8hr (max 3 g/day) [[‡]PMA (Post-Menstrual Age) = gestational age + postnatal age]
 - If renal function present, substitute Vancomycin with Linezolid IV: <12 yrs old: 30 mg/kg/day div q8hr (max 600 mg/dose); ≥12 yrs old: 600 mg q12hr (if ≥12 yrs old and <45 kg: 20 mg/kg/day div q12hr, max 600 mg/dose)

If Orbital Cellulitis with concern for CNS involvement on imaging:

• Treat off pathway and consult Neurosurgery and Infectious Diseases (see Appendix A for work up and antibiotic considerations)

10 yrs: 10 mg/kg once daily (max 750 mg/day)

If PCN at lergy, or if on Clindonycin IV with Ceftrianone:
 Clindonycin PO 3-40 mg/lgs/day did q-6-8th (max 600 mg/dose) AND
 Ceftifin PO 14 mg/kg/day did BID (max 300 mg/dose) or Levofl oracidn PO 6 m o-4 yrs 20 mg/kg/day div q12hr; 5-9 yrs 14 mg/kg/day div q12hr;

If on Vancomycin:

 ADD Clindamycin PO 30-40 mg/kg/day div q6-8hr (max 600 mg/dose) [continue Amoxicillin/Clavulanate or Cefdinir/Levollaxacin as appropriate
 Discharge Instructions:

Follow up with PCP; Complete course of antibiotics, Ophthalmology f/u in 1-2 weeks if involved during admission

The same of the sa




The pharmacy's vancomycin protocol was updated in Feb 2021.

- All patients who have vancomycin IV ordered will be followed by the clinical pharmacist to help determine appropriate dosing parameters.
- Providers will order initial doses per pathway/order set and provide indication within the order.
- IV vancomycin dosing and recommended labs will be managed by pharmacy in conjunction with primary teams.

CLINICAL PATHWAY: Preseptal & Orbital Cellulitis

THIS PATHWAY
SERVES AS A GUIDE
AND DOES NOT
REPLACE CLINICAL
JUDGMENT.



Inpatient Management:

- Patients >5 years old: General pediatric provider (resident, APP) to complete vision checks with Snellen chart on admission and BID (If unable to complete, must document in chart.)
- Continue to monitor for development of orbital cellulitis
- NPO after midnight if strong possibility of surgery
- If orbital cellulitis confirmed on CT:
 - Dexa methasone IV 0.5 mg/kg x1 (max 10 mg/dose) if not already given
 - Consult Infectious Diseases (ID)
 - If signs of systemic illness or intracranial infection, obtain blood culture before antibiotics given, if possible.
- If recent history of trauma or surgery: consult ID as antibiotic recommendations would be different than those listed below

Preseptal or Orbital Cellulitis without CNS involvement on imaging:

- Ampicillin/Sulbactam IV based on ampicillin component: 200 mg/kg/day div q6hr (max 2,000 mg ampicillin/dose)
 - If preseptal cellulitis and stable: can choose Amoxicillin/Clavulanate PO: <40 kg or unable to take tablets: 600 mg/5 mL (ES) suspension: 90 mg/kg/day div BID (max 1000 mg/dose); >40 kg and can take tablets: 875 mg BID tablets
 - If PCN allergy: Clindamycin PO/IV 30-40 mg/kg/day div q8hr (max 600 mg/dose) AND Ceftriaxone IV 75 mg/kg/day div q12hr (max 2 g/DAY)
- If concern for MRSA, obtain MRSA nasal PCR. If PCR positive, obtain MRSA nasal culture and add the below:
 - If preseptal and stable: add Clindamycin PO/IV 30 mg/kg/day div q8hr (max 600 mg/dose) until susceptibilities finalize (unless already on Clindamycin for PCN allergy)
 - If ill-appearing or orbital: add Vancomycin IV: <52 weeks PMA[†]/about <3 mo old: 15 mg/kg q8hr or as determined by pharmacy based on estimated AUC; ≥52 weeks PMA[†]/about ≥3 months old 11 years old: 70 mg/kg/day div q6hr (max 3 g/day); ≥12 yrs old: 60 mg/kg/day div q8hr (max 3 g/day) [[‡]PMA (Post-Menstrual Age) = gestational age + postnatal age]
 - If renal function present, substitute Vancomycin with Linezolid IV: <12 yrs old: 30 mg/kg/day div q8hr (max 600 mg/dose); ≥12 yrs old: 600 mg q12hr (if ≥12 yrs old and <45 kg: 20 mg/kg/day div q12hr, max 600 mg/dose)

If Orbital Cellulitis with concern for CNS involvement on imaging:

Treat off pathway and consult Neurosurgery and Infectious Diseases (see Appendix A for work up and antibiotic considerations)

1) on vontrongers:

ADD Cindamych PO 30-40 mg/kg/day div q6-8hr (max 600 mg/dose) (continue Amoxicilin/Clavulanate or Celdinir/Levollaxadın as appropriate)

Discharge Instructions:

Follow up with PCP: Complete course of antibiosics, Ophthalmoday (Vi. in 1-2 weeks if involved during admission

CONTACTS: MAJIDA GAFFAR, MD I ERIC HOPPA, MD I EBLA ABD ALRAHMAN, MD I SCOTT SCHOEM, MD

AST UPDATED: 09.27.21

©2019 Connecticut Children's Medical Center. All rights reserved.





- Would expect clinical improvement within 48 hours of starting appropriate therapy.
- If there is no improvement, would consider imaging studies to further assess, and utilize a collaborative approach for further management decisions.

CLINICAL PATHWAY:

Preseptal & Orbital Cellulitis

THIS PATHWAY SERVES AS A GUIDE AND DOES NOT REPLACE CLINICAL JUDGMENT

Exclusion Ofteria: evidence of non-cellulitic cause of eye swelling (e.g., allergy, chalazion, conjunctivitis, dacryocele), supero-lateral abscess on CT (will need orbital surgeon), posterior table erosion of the frontal sinus bone with brain abscess, any patient requiring neurosurgical involvement Initial Evaluation Onht halm older History including diplopia, systemic symptoms consult for Physical exam findings, including: Extent of eyelid edema/erythema for any orbital Presence of proptosis Involvemen Ocular motility/pain with eye movement (clinically or Pupillary reaction/afferent pupillary defect on CT) OR If ENT taking to OR Vision with Snellen chart, if possible labs: CBC w/differential, CRP (unless mild pre septal cellulitis signs and/or attending discretion); If ocular discharge, obtain bacterial culture Signs of orbital cellulitis (≥1)? Likely Preseptal Cellulitis due to dental, If high clinical suspicion: 1) Pain w/eye movement Formally consult sinus source ophthalmology If source of infection from skin (e.g., Notify ENT via call 3) Propto sis trauma, bug bite, acne), treat off 4) ANC >10,000/μL or CRP >7 mg/dl pathway and follow Skin and Soft Obtain orbital CT with IV) Cannot assess d/t extensive ssue Infection Pathway contrast eyelid e de ma cellulitis arm of CTpositive fo pathway AND orbital cellulitis? Meets admission criteria notify ophtho of pidly progressing, dehydrated, concern Formally consult EN mg/kg x1 (max 10 mg dose) Discharge on PO antibiotic Admit to PHM servi IF ORBITAL INVOLVEMENT but surgery not (see discharge instructions below) f Skin/soft tissue infection, follow Sk vet indicated. ENT/Oohtho will continue to Inpatient Management: Patients > 5 years old: General pediatric provider to complete vision checks with Snellen chart on admission and BID *(If unable to* complete, must document in chart.) Continue to monitor for development of orbital cellulitis NPO after midnight if strong possibility of surgery if orbital cellulitis confirmed on CT: dexamethasone IV 0.5 mg/kg x1 (max 10 mg/dose) if not already given Pre-Septal or Orbital Cellulitis without CNS involvement on Ampicillin/Sulbactam based on ampicillin Clinical Consider CT or MRI N allergy: Clindamycin PO/IV 30-40 m improvement within If rapidly progressing, obtain CT Discuss with consulting services If Orbital Cellulitis with co Ceftriaxone IV 100 mg/kg/day div q12hr if concern for MRSA, consider addition of ONE time dose with subsequent doses directed by ASI Vancomycin IV: <52 weeks PMA[†]/about <3 m o old: 15 mg/kg x1: ≥52 weeks PMA[†]/about ≥3 m onths old = 11 years old: 17. mg/kg x1 (max 750 mg/dose); ≥12 yr s old: 20 mg/kg x1 (max 1 g/dose) Consult Neurosurgery and Infectious Disease MA (Post-Menstrual Age) = gestational age + postnatal age Consider CT or MRI provement within If rapidly progressing, obtain CT Discuss with consulting services Discharge Criteria: Vision back to ba seline, clinical improvement, afebrile, follow up plan in place Discharge Antibiotics: [Duration: 10 days or longer as determined by ENT based on extensiveness of disease Preferred PO antibiotic if no PCN allergy, OR If on Ampicillin/Sulbactam (Unasyn): Preferred: Amoxicillin/Clavulanate PO ES (600 mg/5 ml) 90 mg/kg/day div TID (max1g of amoxicillin/dose); Alternate if ≥40 kg: Amoxicillin/Clavulanate PO (500/125 tablets) 1 tablet PO TID If PCN atlergy, or if on Clindamycin IV with Ceftriaxone. Clindamycin PO 30-40 mg/kg/day div q6-8hr (max 600 mg/dose) AND Cefdinir PO 14 mg/kg/day div BID (max 300 mg/dose) or Levofl axa an PO 6 mo-4 yrs: 20 mg/kg/day div q12hr; 5-9 yrs: 14 mg/kg/day div q12hr; 10 yrs: 10 mg/kg once daily (max 750 mg/day) ADD Clindamycin PO 30-40 mg/kg/day div q6-8hr (max 600 mg/dose) (continue Amoxicillin/Clavulanate or Cefdinir/Levoflaxacin as appropriate Discharge Instructions:

CONTACTS: MAJIDA GAFFAR, MD | ERIC HOPPA, MD | EBLA ABD ALRAHMAN, MD | SCOTT SCHOEM, MD

Follow up with PCP; Complete course of antibiotics, Ophthalmology f/u in 1-2 weeks if involved during admission

LAST LIDDATED: 00 07 04


Connecticut

©2019 Connecticut Children's Medical Center. All rights reserved.

- If the patient continues to improve on appropriate therapy, start preparing for discharge.
- Ensure the patient's vision is back to baseline and that they are able to tolerate antibiotics by mouth.

CLINICAL PATHWAY: Preseptal & Orbital Cellulitis

THIS PATHWAY SERVES AS A GUIDE AND DOES NOT REPLACE CLINICAL JUDGMENT



<u>DISCHARGE CRITERIA</u>: Vision back to baseline, clinical improvement, afebrile, follow up plan in place <u>DISCHARGE INSTRUCTIONS</u>: Follow up with PCP; Complete course of antibiotics, Ophthalmology f/u in 1-2 weeks if involved during admission <u>DISCHARGE ANTIBIOTICS</u> (not to be used if there is CNS involvement):

- **Duration:** 5-7 days for preseptal cellulitis (if sinusitis, longer therapy may be needed per ENT/ID); ≥2 weeks for orbital cellulitis as determined by ENT/ID
- If sensitivities are available, discuss appropriate antibiotic choice with Infectious Diseases/ASP.
- Preferred PO antibiotic if no PCN allergy or if on Ampicillin/Sulbactam (Unasyn): Amoxicillin/Clavulanate PO: <40 kg or unable to take tablets: 600 mg/5 mL (ES) suspension: 90 mg/kg/day div BID (max 1000 mg/dose); >40 kg and can take tablets: 875 mg BID tablets
- If PCN allergy and IV vancomycin or clindamycin not used: Consider Penicillin Allergy Delabeling Pathway to assess if patient can utilize amox/clav. If PCN allergy confirmed: start cefuroxime PO 30 mg/kg/day div 2 doses (max 500 mg/dose) [Note: only 250 and 500 mg tablets are commercially available; ensure availability for home prior to discharge]. If cefuroxime not available, consult ID.
- If patient was on IV Vancomycin/IV Clindamycin or MRSA nasal PCR/culture positive: discuss with ID to add anti-MRSA antibiotic to antibiotic regimen.



Review of Key Points



- Indications for obtaining a CT of the orbits with IV contrast:
 - Pain with EOM or restricted EOM
 - Proptosis
 - ANC > 10,000/μL or CRP >7 mg/dL
 - Inability to assess due to edema
- Antibiotic selection should be based on likely source
 - If sinus or dental source, ampicillin/sulbactam is the most appropriate for preseptal or orbital cellulitis without CNS involvement.
 - If concern for CNS infection, consult ID for recommendations
 - If there is ever a concern for MRSA, obtain MRSA nasal PCR or PCR from eye discharge and add Vancomycin

Quality Metrics



- Percentage of patients with pathway order set usage
- Percentage of patients with ophthalmology consult
- Percentage of patients who require surgery
- Percentage of patients with appropriate antibiotic choice per pathway recommendation
- Percentage of patients with appropriate antibiotic duration per pathway recommendation
- Inpatient average length of stay (days)
- Number of returns to ED within 48 hours
- Number of returns to ED within 3 weeks

Pathway Contacts



- Majida Gaffar, MD
 - Division of Ophthalmology
- Eric Hoppa, MD
 - Pediatric Emergency Medicine
- Julie Quistorff, APRN
 - Pediatric Hospital Medicine
- Scott Schoem, MD
 - Division of Otolaryngology (ENT)

References



- Botting AM, McIntosh D, Mahadevan M. Paediatric pre- and post-septal peri-orbital infections are different diseases. A retrospective review of 262 cases. Int J Pediatr Otorhinolaryngol, 2008 Mar;72(3):377-83.
- Hamilton S, Taylor M, Schneider, JG, et al. Assessing the Diagnostic Performance and Clinical utility of Nasal Methicillin-Resistant Staphylococcus aureus PCR Testing in Pediatric Orbital Cellulitis. Journal of Pediatric Infectious Diseases Society. 2024 Aug; 13(8):430-433.
- Nageswaran S, Woods CR, Benjamin DK Jr, Givner LB, Shetty AK. Orbital cellulitis in children. *Pediatr Infect Dis J*, 2006 Aug;25(8):695-9.
- Rudloe TF, Harper MB, Prabhu SP, Rahbar R, Vanderveen D, Kimia AA. Acute periorbital infections: who needs emergent imaging? *Pediatrics*, 2010 Apr;125(4):e719-726.

Thank You!



About Connecticut Children's Pathways Program

Clinical pathways guide the management of patients to optimize consistent use of evidence-based practice. Clinical pathways have been shown to improve guideline adherence and quality outcomes, while decreasing length of stay and cost. Here at Connecticut Children's, our Clinical Pathways Program aims to deliver evidence-based, high value care to the greatest number of children in a diversity of patient settings. These pathways serve as a guide for providers and do not replace clinical judgment.